LobbyingAmryt Pharma lobbying by quarter
Amryt Pharma's latest lobbying report covers Q4 2023, at $40K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
Amryt Pharma
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $80K | 2 |
| Q1 2023 | $70K | 2 |
| Q2 2023 | $40K | 1 |
| Q3 2023 | $40K | 1 |
| Q4 2023 | $40K | 1 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$210K · 7 reports
- Medicare and Medicaid$60K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES7 reports
- SENATE7 reports
- Food & Drug Administration (FDA)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Splitoak Strategies | $200K | 5 quarters |
| In-houseAmryt Pharma | $70K | 2 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| AMY JENSEN | 1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Legislative Affairs | Q4 2023 |
| KRISTEN ELIZABETH SHATYNSKI | Professional Staff, House E&C Committee to Cathy McMorris Rodgers (2021-22) & Greg Walden (2017-21); Leg. Asst., Rep. Greg Walden, 4/2015-1/2017; Leg. Asst., Rep. Jackie Walorski, 10/2013-4/2015; Leg. Asst., Rep. Devin Nunes, 10/2012-10/2013 | Q4 2023 |
| SARAH KUEHL EGGE | Legislative Assistant to Senator Bob Kerrey; Senior Budget Analyst for Democratic staff of the Senate Budget Committee (Sen. Kent Conrad); Deputy Staff Director, Joint Select Committee on Deficit Reduction | Q4 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/02/28for Q4 2023 | Splitoak Strategies | $40K |
| 24/01/22for Q4 2023 | Splitoak Strategies | $40K |
| 23/10/20for Q3 2023 | Splitoak Strategies | $40K |
| 23/07/20for Q2 2023 | Splitoak Strategies | $40K |
| 23/04/20for Q1 2023 | Splitoak Strategies | $40K |
| 23/03/03for Q1 2023 | In-house | $30K |
| 23/01/20for Q4 2022 | Splitoak Strategies | $40K |
| 23/01/20for Q4 2022 | In-house | $40K |